NEURONETICS, INC.

Analyst Reco. Neuronetics, Inc.

Equities

STIM

US64131A1051

Real-time Estimate Cboe BZX Other stock markets 08:36:56 29/04/2024 pm IST			5-day change	1st Jan Change
3.53 ^USD	+1.15%		-5.61%	+21.72%

10/04	Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation	CI
28/03	Neuronetics, Inc. Announces John K. Bakewell, Joseph H. Capper and Dr. Wilfred E. Jaeger Not Stand for Reelection to the Board	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Canaccord Genuity Adjusts Price Target on Neuronetics to $7 From $9, Maintains Buy Rating	08/23/08	MT
Piper Sandler Adjusts Neuronetics' Price Target to $9 From $10, Reiterates Overweight Rating	03/22/03	MT
NEURONETICS : JMP Securities Adjusts Price Target on Neuronetics to $12 From $18, Maintains Market Outperform Rating	14/21/14	MT
NEURONETICS : William Blair Downgrades Neuronetics to Market Perform From Outperform	13/21/13	MT
NEURONETICS : BTIG Downgrades Neuronetics to Neutral from Buy	13/21/13	MT
NEURONETICS : William Blair Upgrades Neuronetics to Outperform From Market Perform	22/21/22	MT
NEURONETICS : Piper Sandler Adjusts Neuronetics' Price Target to $27 from $20, Keeps Overweight Rating	21/21/21	MT
NEURONETICS : BTIG Research Adjusts Neuronetics PT to $21 From $14, Maintains Buy Rating	21/21/21	MT
NEURONETICS : BTIG Research Adjusts Neuronetics PT to $14 From $10, Maintains Buy Rating	07/20/07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer